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ABSTRACT
Aims To describe, in the context of DSM-V, how a focus on addiction and compulsion is emerging in the consideration
of pathological gambling (PG).Methods A systematic literature review of evidence for the proposed re-classification
of PG as an addiction. Results Findings include: (i) phenomenological models of addiction highlighting a motiva-
tional shift from impulsivity to compulsivity associated with a protracted withdrawal syndrome and blurring of the
ego-syntonic/ego-dystonic dichotomy; (ii) common neurotransmitter (dopamine, serotonin) contributions to PG and
substance use disorders (SUDs); (iii) neuroimaging support for shared neurocircuitries between ‘behavioural’ and
substance addictions and differences between obsessive–compulsive disorder (OCD), impulse control disorders (ICDs)
and SUDs; (iv) genetic findingsmore closely related to endophenotypic constructs such as compulsivity and impulsivity
than to psychiatric disorders; (v) psychological measures such as harm avoidance identifying a closer association
between SUDs and PG than with OCD; (vi) community and pharmacotherapeutic trials data supporting a closer
association between SUDs and PG than with OCD. Adapted behavioural therapies, such as exposure therapy, appear
applicable to OCD, PG or SUDs, suggesting some commonalities across disorders. Conclusions PG shares more simi-
larities with SUDs than with OCD. Similar to the investigation of impulsivity, studies of compulsivity hold promising
insights concerning the course, differential diagnosis and treatment of PG, SUDs, and OCD.
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INTRODUCTION
Debate exists regarding the appropriateness of consider-
ing pathological gambling (PG) as an impulse control,
obsessive–compulsive-spectrum or addictive disorder
[1,2] as features of impulsivity, compulsivity and addic-
tion are observed in PG [3]. This debate is timely, as the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) develops [4,5]. Proposed changes include the
reclassification of PG from the Impulse Control Disorders
(ICDs) category to one of ‘Addiction and Related Dis-
orders’ [1] and obsessive–compulsive disorder (OCD)
from the anxiety disorder category to one of obsessive–
compulsive spectrum disorders (OCSDs) [6], where ICDs
characterized by excessive shopping, internet use or
sexual behaviour could be included [7]. Emerging from
these proposed changes is an increasing focus on addic-
tion and compulsion in the consideration of ICDs within
the new nomenclature. Here we examine the potential
overlap of compulsivity and addiction in relation to PG,
substance use disorders (SUDs) and OCD along phenom-
enological and neurobiological lines, and discuss treat-
ment implications.
COMMONALITIES BETWEEN
DEFINITIONS AND CRITERIA
A feature of substance dependence in the DSM-IV-TR is
that ‘use is continued despite knowledge of having a per-
sistent or recurrent physical or psychological problem’
[8].The term ‘addiction’ avoids confusion relating to non-
addictive forms of dependence (e.g. as observed in people
taking beta-adrenergic antagonists for hypertension).
With components related to diminished self-control and
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craving [9], addiction involves compulsive drug use
despite adverse consequences [10], suggesting that addic-
tions are not limited to drug use [4,11]. Similar to drug
addictions, PG can include repeated unsuccessful efforts
to control, cut back or stop gambling; feeling restless or
irritable when attempting to cut down or stop gambling;
and diminished ability to resist an impulse to gamble
despite serious or adverse consequences of the gambling
behaviours [8].
Compulsivity in OCD involves performing unpleas-
antly repetitive acts in a habitual manner to prevent
perceived negative consequences, leading to functional
impairment [12–14]. The traditional psychopathology
perspective associates compulsive behaviours with obses-
sions, cognitions which, as a whole, are characterized by
unrelenting doubts about one’s own perceptions and
behaviours, hesitation, feelings of incompleteness and
over-estimation of risk. Such features are proposed to
have their roots in personality, the so-called ‘anankastic
trait’. The perennial nature of the trait would answer for
the recurrent need to repeat specific behaviours to
domesticate an eternal subjective disquiet, thus delineat-
ing a compulsivity construct [15]. Parallels in phenom-
enology related to OCD, ICDs and substance addictions
may involve engagement in seemingly compulsive behav-
iours to prevent or reduce distress [8], anxiety or stress
prior to participation in the behaviours and relief during
and following performance of the behaviours [9].
PHENOMENOLOGICAL ASPECTS OF
COMPULSIVITY
Is there a motivational shift?
Several models of addiction conceptualize a progression
from impulsivity to compulsivity, transitioning from
initial positive reinforcement motivations to later nega-
tive reinforcement and automaticity mechanisms [9,16–
20]. A protracted withdrawal syndrome may occur,
generating motivational aspects of dependence, through
negative emotional states (e.g. dysphoria, anxiety, irrita-
bility) when access to the drug or addictive behaviour is
prevented. This negative affective state may contribute to
compulsivity through negative reinforcement [9,19,21].
How distinct is the ego-syntonic/
ego-dystonic dichotomy?
While there may be similar compulsive features in PG,
OCD and substance addiction, there are also differences.
Substance and behavioural addictions such as PG have
been described as ego-syntonic, meaning they are often
preceded by feelings of ‘pleasure, gratification, or relief at
the time of committing the act’ [8]. In OCD, compulsive
behaviours are often completed to suppress or neutralize
thoughts and reduce tension and anxiety related to
obsessions [8]. These compulsions are typically consid-
ered ego-dystonic in nature. Thus, the motivations
underlying compulsive behaviours in addictions and OCD
may differ. However, addictive behaviours may become
less ego-syntonic and more ego-dystonic over time, as the
behaviour or effects of the substance becomes less plea-
surable and more habitual or compulsive [9,19,21–23].
Similarly, reference to the compulsions in OCD as
integrally ‘unpleasant’ may not always be the case, as
in childhood OCD, or the relief individuals may obtain
after ‘cleaning just right’ or the satisfaction attached to
arranging until ‘mission accomplished’ [24].
Tolerance and withdrawal
The occurrence of tolerance may be another similarity
between substance addiction, PG andOCD,with a drive to
increase the intensity of the repetitive behaviour over
time [25,26]. An urge or craving while abstaining from
the behaviours may have similarity with cravings during
drug withdrawal in substance addictions [1]. The transi-
tion of drug use to addiction has also been considered
with respect to neuroplasticity where, with repeated
exposure to drugs of abuse, an incentive salience state of
‘wanting’, linked to compulsive use, replaces a ‘liking’ or
hedonic response [27].
NEUROBIOLOGICAL UNDERPINNINGS
OF COMPULSIVITY
Neurotransmitters
Multiple neurotransmitter systems contribute to sub-
stance addiction and PG, many of which are implicated
in OCD; however, data suggest differences in the nature
of the involvement of these systems in PG and OCD [22].
Serotonin (5-HT) contributes to behavioural inhibi-
tion and dopamine (DA) to learning, motivation and
the salience of stimuli, including rewards [28]. Pharma-
cological challenges of 5-HT and dopamine systems
[29–33] suggest differences in the nature of the involve-
ment of these systems in OCD compared to PG and SUDs.
Following a challenge with a serotonergic agonist such
as meta-chlorophenyl piperazine (m-CPP), OCD patients
report an exacerbation of OC symptoms [32]. Individuals
with PG are more likely to report a euphoric or ‘high’
response to m-CPP, similar to responses seen in alcohol-
dependent subjects [30].
Neurocircuitry
Neuroimaging data support a shared neurocircuitry of
behavioural and substance addictions that appears differ-
entially involved in OCD [19]. Frontostriatal circuitry
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contributes to impulsive choice in substance addiction
[17] and PG [34,35]. Dysfunction of striato-thalamo-
cortical circuitry, implicated in perseverative behaviours,
may account for compulsive drug use in addiction [36].
Frontal-striatal circuits are implicated in OCD, ICDs in
Parkinson’s disease (PD) and cocaine-seeking behaviours
[37]. In one model [37], a ventral prefrontal system con-
cerned with emotive factors interacts with a dorsal pre-
frontal executive functioning system. In ICDs in PD, an
imbalance between limbic and motor cortical systems,
related in part to PD pathology and/or the DA replace-
ment therapies used to treat the disorder, may exist [38].
In drug addiction, an imbalance of the ventral andmotor
systemsmay be flexible in time,moving from involvement
of ventral to dorsal circuitry [17,19,39].
Cravings in substance and behavioural addictions
have been associated with diminished ventral striatal
activation [40], similar to findings during reward pro-
cessing or simulated gambling in PG and alcoholism
[41,42]. Gambling task participation may elicit greater
DA release in the ventral striatum in individuals with PD
and PG than in individualswith PD alone [43], a response
similar to that elicited by drugs or drug-associated cues
in drug-addicted individuals [44] or in PD subjects who
take DA replacement drugs excessively [45]. Increased
activation of frontostriatal circuitry has been observed
following cue exposure in OCD [46], whereas diminished
activation has been seen in PG [47], highlighting the
need for concurrent investigation of PG, OCD, drug-
dependent and control subjects [22].
Koob & Volkow [9] argue that impulsivity domi-
nates the early stages of addiction, and impulsivity com-
bined with compulsivity dominates the later stages.
They propose three stages of the addiction cycle:
‘binge/intoxication’, ‘withdrawal/negative affect’ and
‘preoccupation/anticipation’ (craving). In their model,
the ventral tegmental area and ventral striatum contrib-
ute substantially to the binge/intoxication stage, the
extended amygdala (including regions of amygdala, stria
terminalis and nucleus accumbens) contributes substan-
tially to the withdrawal/negative affect stage, and the
preoccupation/anticipation stage involves a widely dis-
tributed network involving the orbitofrontal cortex–
dorsal striatum, prefrontal cortex, basolateral amygdala
and hippocampus. The insula contributes to craving, the
cingulate gyrus, dorsolateral prefrontal and inferior
frontal cortices to poor inhibitory control, and a pro-
tracted withdrawal syndrome with a negative affect state
to compulsivity [9,21].
Consideration of protracted withdrawal in PG is war-
ranted, as psychological withdrawal has been reported
in PG [1,48]. Additionally, gambling in response to
emotional dysregulation [23] and coping with stress
have been cited as precedents of engaging in PG [49].
Similarly, drug-taking in drug addiction and compulsive
behaviours in OCD may be performed to reduce distress
[8].
Lubman et al. [50] caution that, while there are simi-
larities in clinical features and behavioural deficits asso-
ciated with inhibitory control in both addiction and OCD,
functional activity within inhibitory regions is markedly
dissimilar, reflecting differences in core cognitive pro-
cesses relevant to each disorder [50–53]. An under-
activity of the inhibitory system in addiction may be
associated with limited future regard and diminished
ability to resist engaging in drug-related behaviours,
whereas in OCD the system may be overactive, perhaps
because individuals are overly concerned about future
consequences [50].
Genetic vulnerability and endophenotypes
Candidate gene studies of PG suggest links to SUDs and
poor inhibitory control [22]. Some but not other studies
have implicated the Taq-A1 polymorphism of the gene
encoding the DA D2 receptor [54–56]. Variants of the
5-HT transporter gene have been implicated in both OCD
and PG, but the nature of the associations differ [22],
with the long allele found in association with OCD and
the short allele found in association with PG [57,58].
In support of OCSDs, a cluster analysis conducted in
patients with OCD identified three separate clusters [59].
The clusters were termed: reward deficiency (including
trichotillomania, Tourette’s disorder, pathological gam-
bling and hypersexual disorder); impulsivity (including
compulsive shopping, kleptomania, eating disorders, self-
injury and intermittent explosive disorder); and somatic
(including body dysmorphic disorder and hypochondria-
sis). None were associated with any particular genetic
variant studied. Future genetic investigations should con-
sider behavioural dimensions (compulsivity and impul-
sivity) and endophenotypes [60]. Endophenotypes have
the potential to measure objective trait markers that are
either simpler to assess than complex phenotypic behav-
ioural diseases or may represent constructs aligned
more closely with biological underpinnings of psychiatric
disorders [61]. Because endophenotype research in psy-
chiatry is relatively new, limited data are available [62].
An abnormally reduced activation of several cortical
regions, including the orbitofrontal cortex during rever-
sal learning in OCD patients and their clinically un-
affected close relatives, has been identified. In a study
assessing inhibitory control processes, OCD probands and
unaffected first-degree relatives showed cognitive inflex-
ibility (extra-dimensional set shifting) and motor impul-
sivity (stop-signal reaction times). These deficits may
represent endophenotypes for OCD and related conditions
[62,63].
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In a motor inhibition paradigm (the stop-signal
task—SST), both OCD patients and their unaffected first-
degree relatives exhibited impaired motor inhibitory
control, indexed by prolonged latency of the stop-signal
reaction time (SSRT), and longer latency was associated
with both decreased grey-matter volume in the orbito-
frontal cortex and right inferior frontal cortex (areas
associated conventionally with OCD and SST activation,
respectively) and increased grey-matter volume in areas
of the striatum, cingulate and parietal cortex [64]. These
results argue for the first structural magnetic resonance
imaging (MRI) endophenotype mediating familial, and
possibly genetic, risk for OCD-related impulsivity. Data
suggest that such an endophenotype may also be
relevant to PG and SUDs [23].
COMPLEMENTARY DIMENSIONS
OF COMPULSIVITY
Psychological measures
Individuals with OCD score highly on measures of harm
avoidance [65], whereas those with PG approximate
more closely those with SUDs, scoring highly on mea-
sures of impulsivity and novelty seeking [19,47,66].
However, some individuals with OCD display high levels
of cognitive impulsiveness [67], and individuals with PG
or OCD have demonstrated high levels of both impulsiv-
ity and harm avoidance, suggesting a complex relation-
ship between impulsivity and compulsivity [22,68].
Within OCSDs, Hollander & Wong [69] proposed an
organizing axis (the impulsive–compulsive spectrum) in
which psychiatric disorders lie along a spectrum with
OCD at the compulsivity extreme and antisocial person-
ality disorder at the impulsive extreme. However, the
co-occurrence of impulsivity and compulsivity traits
in several addictive disorders challenges this uni-
dimensional model. A study of PG and OCD [68] pro-
posed unfolding the impulsive–compulsive spectrum
into two orthogonal dimensions, yielding three psy-
chopathological domains: predominantly impulsive,
predominantly compulsive (OCD) and impulsive–
compulsive (PG).
Decision-making is relevant to PG, OCD and SUDs
[22]. Similar differences in decision-making reflecting
a propensity to make disadvantageous choices during
gambling task performance have been found between
control subjects and those with PG [70], OCD [71] and
SUDs [72]. However, other studies have found decision-
making to be intact in OCD despite impairment on
other tasks [73,74]. The lack of convergence of these
findings may reflect the heterogeneity of OCD, and
further research is needed investigating compulsivity
and decision-making.
Co-occurring disorders
Clinical and community samples indicate that PG
co-occurs with multiple Axis I and II disorders, with
particularly strong associations with SUDs [75–78].
Unfortunately, diagnostic assessments of OCD have
not been obtained consistently. In the St Louis Epidemio-
logic Catchment Area (ECA) study, whereas elevated
odds ratios (ORs) were observed between problem/
pathological gambling and SUDs, a non-elevated OR
of 0.6 was observed between problem/pathological
gambling and OCD [79].
Although PG and OCD might not have a strong
connection, they share comorbidities. In the National
Comorbidity Survey Replication, a subsample of 2073
respondents was assessed for OCD [80]. More than one-
quarter of respondents reported experiencing life-time
obsessions or compulsions, but only small proportions
of respondents met DSM-IV criteria for life-time (2.3%) or
12-month (1.2%) OCD. OCD was associated with sub-
stantial comorbidity, with the strongest associations with
internalizing (anxiety and mood) disorders and elevated
odds for ICDs and SUDs. Together, these findings suggest
the need for measures of OCD, PG and other substance
and behavioural addictions in population surveys and
further investigation of their relationships.
RESPONSE TO TREATMENT
Pharmacotherapies
Although no drug is indicated formally for PG, three
main classes have been investigated: opioid antagonists,
mood stabilizers and serotonin re-uptake inhibitors (SRIs)
[81,82]. Opioid antagonists such as naltrexone reduce
drinking frequency and likelihood of relapse to heavy
drinking [83,84]. Opioid antagonists also appear effica-
cious in the treatment of PG [1,85–87]. As response to
opioid antagonist treatment appears particularly robust
among individuals with a family history of alcoholism
[88], a treatment-relevant addiction-related endopheno-
type, perhaps related to craving or urges, is suggested.
The treatment-related similarities between PG and
SUDs constrast with OCD findings. Naltrexone does not
influence OCD severity [89] and may exacerbate symp-
toms [90,91]. Mood stabilizers such as lithium may be
helpful in treating PG [92–94] but not OCD [95]. Antip-
sychotic drugs antagonizing DA D2-like receptors (halo-
peridol, risperidone and olanzapine) have shown efficacy
as augmenting agents in OCD [96], but have demon-
strated negative findings in placebo-controlled trials in PG
[97–99] and increase motivations to gamble in PG [100].
SRIs are indicated for treating OCD [96], but have had
mixed results for PG and SUDs [22]. Some randomized
control trials have found fluvoxamine and paroxetine to
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be superior to placebo in the treatment of PG [101,102],
and others have not [103,104]. Differential effects of
pharmacotherapy on PG suggest targeting co-occurring
disorders, such as anxiety [105], when treating PG
[76,106], and concurrent decreases in both PG and the
co-occurring domains have been observed [93,105].
A double-blind, placebo-controlled, counterbalanced
study of an atypical stimulant (modafinil) in PG sug-
gested two subgroups [100]. Subjects with high impulsiv-
ity showed a decrease in motivation to gamble, risky
decision-making, impulsivity and responses to gambling-
related lexical stimuli. Thosewith low impulsivity showed
increased scores on all these measures, suggesting a bidi-
rectional effect of modafinil that differentiates between
high and low impulsive individuals with PG. This finding
suggests heterogeneity in PG, which could explain seem-
ingly conflicting results in clinical trials. Other data
suggest that impulsivity may represent an important
treatment target in PG [107,108]. Emerging data also
suggest roles for glutamatergic therapies in the treatment
of OCD, PG and SUDs [96,109,110], possibly through
targeting compulsivity related measures (e.g. cognitive
inflexibility) [111], although results should be inter-
preted cautiously.
Behavioural interventions
Behavioural therapies efficacious in treating SUDs may
also be helpful for PG and OCD [112,113]. Behavioural
andmotivational therapies, including motivational inter-
viewing (MI) and cognitive–behavioural therapy (CBT),
have been shown to be effective in treating SUDs and
PG [82,114–117]. Attendance in Gamblers Anonymous
(GA), modelled after Alcoholics Anonymous (AA), has
been associated with better outcome for people partici-
pating in professional gambling treatment [118]. OCD
has been treated typically through exposure/response
prevention strategies [119,120], and theoretically
similar imaginal desensitization approaches have support
in PG [121–124].
SUMMARY AND CONCLUSIONS
Significant overlap exists between PG and SUDs, with
compulsivity representing a potentially important
endophenotype. Although OCD and addictions may
share some similarities, they appear neurobiologically dif-
ferent, have lower than expected comorbidity rates and
differ with respect to responses to treatments [125].
However, like impulsivity, compulsivity as an endopheno-
typic construct is important to examine in future studies
of ICDs, SUDs and OCD [28,39,61].
Regarding the putative behavioural addictions, PG
may be the only disorder with enough existing data to
progress with classification as an addiction [1]. Behav-
ioural addictions represent an important focus of future
research. Behavioural addictions may be similar to or dif-
ferent from each other at phenotypical and neurobiologi-
cal levels with existing data suggesting both [126]. It is
likely that as with OCD and other psychiatric disorders,
each behavioural addiction will represent a heteroge-
neous disorder [127,128]. Such heterogeneity should be
recognized while investigating the precise categorizations
of the disorders and the development of optimally effec-
tive prevention and treatment strategies. Neurobiological
advances may help in the understanding of heterogene-
ities and guide treatment development. Cognitive and
behavioural approaches mindful of specific symptom
clusters and recognizing the symptomatic evolution
of the impulsivity–compulsivity constructs may lead
to enhanced effectiveness. Recent models of impulsivity
suggest the construct is not uni-dimensional [129,130].
Compulsivity is likely to be multi-dimensional, with com-
ponents reflecting motivationally driven, repetitive per-
formance of behaviours. Compulsivity, like impulsivity,
may represent an important endophenotype for ICDs,
SUDs and OCD ([28,39,61]). As endophenotypes repre-
sent intermediary constructs between complex disorders
and genotypes, they may track more closely to biological
constructs and be improved targets for prevention and
treatment interventions.
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